NASDAQ:NKTR - Nektar Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $60.60 +0.57 (+0.95 %) (As of 08/20/2018 04:00 PM ET)Previous Close$60.03Today's Range$59.75 - $60.8552-Week Range$17.51 - $111.36Volume1.53 million shsAverage Volume3.43 million shsMarket Capitalization$10.31 billionP/E Ratio-109.71Dividend YieldN/ABeta2.08 Company ProfileAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology. It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia. In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis. Further, it is developing SEMPRANA to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with AstraZeneca AB, Shire plc, Pfizer Inc., Amgen Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, Bristol-Myers Squibb Company, and Takeda Pharmaceutical Company Limited. The company was founded in 1990 and is headquartered in San Francisco, California. Receive NKTR News and Ratings via Email Sign-up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical SymbolNASDAQ:NKTR CUSIP64026810 Webwww.nektar.com Phone415-482-5300 Debt Debt-to-Equity Ratio0.13 Current Ratio19.67 Quick Ratio19.55 Price-To-Earnings Trailing P/E Ratio-109.71 Forward P/E Ratio17.77 P/E GrowthN/A Sales & Book Value Annual Sales$30.71 million Price / Sales340.33 Cash FlowN/A Price / CashN/A Book Value$0.56 per share Price / Book108.21 Profitability EPS (Most Recent Fiscal Year)($0.55) Net Income$-96,690,000.00 Net Margins65.69% Return on Equity174.70% Return on Assets93.63% Miscellaneous Employees509 Outstanding Shares172,470,000Market Cap$10.31 billion Nektar Therapeutics (NASDAQ:NKTR) Frequently Asked Questions What is Nektar Therapeutics' stock symbol? Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR." How were Nektar Therapeutics' earnings last quarter? Nektar Therapeutics (NASDAQ:NKTR) posted its quarterly earnings results on Wednesday, August, 8th. The biopharmaceutical company reported $5.33 EPS for the quarter, topping the consensus estimate of $5.22 by $0.11. The biopharmaceutical company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.03 billion. Nektar Therapeutics had a net margin of 65.69% and a return on equity of 174.70%. The business's revenue was up 3043.7% compared to the same quarter last year. During the same period last year, the firm posted ($0.39) earnings per share. View Nektar Therapeutics' Earnings History. When is Nektar Therapeutics' next earnings date? Nektar Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November, 6th 2018. View Earnings Estimates for Nektar Therapeutics. What price target have analysts set for NKTR? 11 analysts have issued 12-month price objectives for Nektar Therapeutics' shares. Their forecasts range from $45.00 to $125.00. On average, they expect Nektar Therapeutics' share price to reach $85.80 in the next twelve months. This suggests a possible upside of 41.6% from the stock's current price. View Analyst Price Targets for Nektar Therapeutics. What is the consensus analysts' recommendation for Nektar Therapeutics? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 1 hold rating and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nektar Therapeutics. What are Wall Street analysts saying about Nektar Therapeutics stock? Here are some recent quotes from research analysts about Nektar Therapeutics stock: 1. Mizuho analysts commented, "We highlighted results in our previous note here. Nektar, in collaboration with Bristol Myers, is expected to initiate a phase 3 registrational trial in first- line melanoma in 3Q18. In addition, pivotal studies are also currently being designed and expected to start in 2018 for renal cell carcinoma (RCC) and urothelial cancer (UC)." (8/9/2018) 2. HC Wainwright analysts commented, "Our 12-month, $54 price target on the shares of Nektar is based on a 13-year DCF-driven, sum-of-the-parts analysis. Our DCF is driven by beta of 1.15, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 8.6%, and tax rate of 15% beginning in FY 2023. Pending further data updates, we are eliminating NSCLC from our model, which represented about 30% of our valuation in our prior model. Cancer together represent about 64% of our target." (7/31/2018) 3. According to Zacks Investment Research, "Nektar has a promising pipeline with several updates lined up for the next several quarters. Additionally, regular partnerships have enhanced the company’s financial position. Nektar stands to receive significant sales milestone payment plus royalties for Movantik under the license agreement with AstraZeneca. Also, its recent co-development deal with Lilly for NKTR-358 and Bristol-Myers for NKTR-214 is encouraging. The deals provide revenues as well as reduce expenses by sharing research costs. On the flip side, Nektar relies heavily on partners for revenues. Partnership-related setbacks may thus weigh heavily on the company. Shares of the company have outperformed the industry in the past one year. Estimates have remained stable ahead of the company’s Q2 earnings release. Nektar has a mixed record of earnings surprises in recent quarters." (7/16/2018) Who are some of Nektar Therapeutics' key competitors? Some companies that are related to Nektar Therapeutics include Regeneron Pharmaceuticals (REGN), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), GRIFOLS S A/S (GRFS), Merck KGaA (MKGAF), Ono Pharmaceutical (OPHLF), Jazz Pharmaceuticals (JAZZ), Genmab A/S (GNMSF) and Alnylam Pharmaceuticals (ALNY). Who are Nektar Therapeutics' key executives? Nektar Therapeutics' management team includes the folowing people: Mr. Howard W. Robin, CEO, Pres & Director (Age 65)Mr. Gil M. Labrucherie, Sr. VP & CFO (Age 46)Mr. John Nicholson, Sr. VP & COO (Age 66)Dr. Stephen K. Doberstein, Sr. VP of R&D and Chief R&D Officer (Age 59)Dr. Maninder Hora, Sr. VP of Pharmaceutical Devel. & Chief Technical Operations Officer (Age 64) Has Nektar Therapeutics been receiving favorable news coverage? News headlines about NKTR stock have been trending somewhat positive on Monday, Accern reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Nektar Therapeutics earned a news impact score of 0.20 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 46.22 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Nektar Therapeutics. Who are Nektar Therapeutics' major shareholders? Nektar Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), BlackRock Inc. (7.39%), OppenheimerFunds Inc. (6.74%), Janus Henderson Group PLC (2.86%), Morgan Stanley (0.70%) and Bank of New York Mellon Corp (0.68%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Dennis L Winger, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess, Roy A Whitfield and Stephen K Doberstein. View Institutional Ownership Trends for Nektar Therapeutics. Which institutional investors are selling Nektar Therapeutics stock? NKTR stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Voya Investment Management LLC, Janus Henderson Group PLC, Schwab Charles Investment Management Inc., Rothschild Asset Management Inc., Bank of America Corp DE, Federated Investors Inc. PA and Eagle Asset Management Inc.. Company insiders that have sold Nektar Therapeutics company stock in the last year include Christopher A Kuebler, Dennis L Winger, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jillian B Thomsen, John Nicholson, Maninder Hora, R Scott Greer, Robert Chess and Stephen K Doberstein. View Insider Buying and Selling for Nektar Therapeutics. Which institutional investors are buying Nektar Therapeutics stock? NKTR stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, OppenheimerFunds Inc., Advisors Asset Management Inc., BB Biotech AG, Sumitomo Mitsui Trust Holdings Inc., Tobam, Frontier Capital Management Co. LLC and Paloma Partners Management Co. Company insiders that have bought Nektar Therapeutics stock in the last two years include R Scott Greer and Roy A Whitfield. View Insider Buying and Selling for Nektar Therapeutics. How do I buy shares of Nektar Therapeutics? Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Nektar Therapeutics' stock price today? One share of NKTR stock can currently be purchased for approximately $60.60. How big of a company is Nektar Therapeutics? Nektar Therapeutics has a market capitalization of $10.31 billion and generates $30.71 million in revenue each year. The biopharmaceutical company earns $-96,690,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Nektar Therapeutics employs 509 workers across the globe. How can I contact Nektar Therapeutics? Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected] MarketBeat Community Rating for Nektar Therapeutics (NASDAQ NKTR)Community Ranking: 3.3 out of 5 ( )Outperform Votes: 454 (Vote Outperform)Underperform Votes: 230 (Vote Underperform)Total Votes: 684MarketBeat's community ratings are surveys of what our community members think about Nektar Therapeutics and other stocks. Vote "Outperform" if you believe NKTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NKTR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/20/2018 by MarketBeat.com StaffFeatured Article: How are Outstanding Shares Different from Authorized Shares?